🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Parnax Lab Limited PARNAXLAB NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.naxparlab.com
Company Profile ↓
₹104.05
-14.71% 1Y
Mkt Cap₹119.51 Cr
P/E13.36
P/B1.42
52W High₹140.78
52W Low₹103.94
Book Value₹83.05
EPS (TTM)₹7.79

Company Overview

Parnax Lab Limited engages in the manufacture and export of pharmaceutical formulations in India and internationally. The company offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; cosmetic; herbal; and nutraceutical products. It also provides oral formulations, such as cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, formulations for geriatrics, highly viscous products, and suspensions. In addition, the company provides drug identification and development services; in- and out-licensing services; and contract research and manufacturing services. The company was formerly known as Krishna-Deep Trade & Investments Limited and changed its name to Parnax Lab Limited in April 2012. Parnax Lab Limited was incorporated in 1982 and is headquartered in Mumbai, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 11.0% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 14.0% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 13.4, below the sector median of 35.9.

Recent Developments

  • Mar 2026 Revenue of ₹248.54 Cr (+32.4% YoY); net profit ₹11.78 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +6.4%, earnings -87.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 14.0%, profit CAGR 11.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:14.03%
1 Year:6.40%

Compounded Profit Growth

5 Years:10.97%
1 Year:-87.00%

Stock Price Performance

1 Year:-14.71%
6 Months:-
3 Months:-
1 Month:-12.13%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 0% of range
₹103.94 ₹140.78
Trend Signals
  • RSI (14)36.76 · Neutral
Price Performance
1M-12.13%
1Y-14.71%
Valuation vs Sector

P/E of 13.36 is below the sector median of 35.90 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 14.0% over 5 years.
  • Profit CAGR of 11.0% over 5 years.

CONS

  • Trading 26.1% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
13.36
Industry PE
35.90
Forward P/E est.
26.72
PEG Ratio
-
Book Value
₹83.05
Price to Book
1.42
P/S
0.59
EV/EBITDA
8.92
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
14.03%
Profit 5Y
10.97%
Revenue (YoY)
6.40%
Earnings (YoY)
-87.00%

Profitability & Returns

ROCE
14.57%
ROE
12.38%
ROA
5.17%
Profit Margin
3.55%
Op Margin
3.67%
Gross Margin
40.71%
EPS (Latest Qtr)
₹-
EPS (TTM)
₹7.79

Balance Sheet & Liquidity

Debt/Equity
0.87
Quick Ratio
0.59
Current Ratio
0.97
Debt
₹82.78 Cr
Total Assets
₹227.63 Cr
Current Assets
₹93.04 Cr
Working Capital
₹-2.80 Cr

Ownership

Promoter Holding
85.34%
Chg in Prom Hold
-
FII / Inst Holding
0.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹119.51 Cr
Total Revenue (TTM)
₹251.97 Cr
EBITDA
₹24.31 Cr
Free Cash Flow
₹-9.31 Cr
Operating Cash Flow
₹8.00 Cr
Shares Outstanding
₹1.15 Cr
Gross Margin
40.71%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 PARNAXLAB Parnax Lab Limited NSEPHARMA 104.05 13.36 ₹119.51 Cr 0.00% 14.57% 12.38% 14.03% 10.97%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,758.00 34.88 ₹4.22 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,162.00 83.32 ₹2.43 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,615.30 73.73 ₹1.76 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,135.00 25.30 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 634.25 165.17 ₹1.10 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,604.50 52.35 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,002.50 98.99 ₹1.08 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,330.90 31.92 ₹1.08 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -49.04 Cr53.38 Cr62.60 Cr62.94 Cr69.63 Cr
Cost of Revenue -26.28 Cr29.98 Cr36.32 Cr37.33 Cr43.45 Cr
Gross Profit -22.76 Cr23.39 Cr26.28 Cr25.61 Cr26.17 Cr
Operating Expenses -17.95 Cr17.90 Cr20.30 Cr20.72 Cr23.33 Cr
Operating Income -4.80 Cr5.49 Cr5.98 Cr4.89 Cr2.85 Cr
EBITDA -7.06 Cr7.62 Cr8.71 Cr6.68 Cr6.65 Cr
Interest Expense -1.28 Cr1.22 Cr1.40 Cr1.47 Cr1.61 Cr
Pretax Income -3.95 Cr4.46 Cr5.20 Cr3.25 Cr3.00 Cr
Tax Provision -1.03 Cr1.18 Cr1.58 Cr53.29 L81.38 L
Net Income -2.92 Cr3.27 Cr3.63 Cr2.71 Cr2.18 Cr
Diluted EPS ------

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -167.61 Cr188.71 Cr187.74 Cr248.54 Cr
Cost of Revenue -116.34 Cr133.28 Cr96.00 Cr147.09 Cr
Gross Profit -51.27 Cr55.43 Cr91.74 Cr101.45 Cr
Operating Expenses -34.52 Cr38.76 Cr72.35 Cr82.25 Cr
Operating Income -16.75 Cr16.67 Cr19.39 Cr19.20 Cr
EBITDA -23.71 Cr24.28 Cr28.44 Cr29.66 Cr
Interest Expense -4.90 Cr5.26 Cr5.39 Cr5.71 Cr
Pretax Income -12.28 Cr12.05 Cr15.67 Cr15.91 Cr
Tax Provision -3.65 Cr2.42 Cr4.13 Cr4.11 Cr
Net Income -8.62 Cr9.61 Cr11.52 Cr11.78 Cr
Diluted EPS 9.687.798.3710.05-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -145.07 Cr190.26 Cr189.82 Cr227.63 Cr
Current Assets -61.06 Cr76.93 Cr68.34 Cr93.04 Cr
Cash & Equivalents -1.28 Cr45.78 L54.99 L33.64 L
Inventory -21.69 Cr29.93 Cr25.77 Cr36.22 Cr
Receivables -27.89 Cr32.56 Cr30.76 Cr37.81 Cr
Total Liabilities -82.81 Cr118.57 Cr106.58 Cr132.33 Cr
Current Liabilities -63.04 Cr83.33 Cr74.33 Cr95.85 Cr
Long Term Debt -12.02 Cr21.05 Cr17.99 Cr21.73 Cr
Total Debt -54.72 Cr80.64 Cr69.53 Cr82.78 Cr
Total Equity -62.15 Cr71.57 Cr83.10 Cr95.14 Cr
Shares Outstanding -1.15 Cr1.15 Cr1.15 Cr1.15 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -20.91 Cr15.88 Cr32.30 Cr8.00 Cr
Investing Cash Flow --9.92 Cr-31.52 Cr-16.39 Cr-16.39 Cr
Financing Cash Flow --14.07 Cr14.82 Cr-15.82 Cr8.18 Cr
Capital Expenditure --11.28 Cr-32.49 Cr-18.58 Cr-17.31 Cr
Free Cash Flow -9.63 Cr-16.62 Cr13.72 Cr-9.31 Cr
Net Change in Cash --3.08 Cr-82.17 L9.21 L-21.35 L

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -30.6%29.4%48.9%40.8%
Operating Margin % -10.0%8.8%10.3%7.7%
Net Margin % -5.1%5.1%6.1%4.7%
ROE % -13.9%13.4%13.9%12.4%
ROCE % -20.4%15.6%16.8%14.6%

Shareholding Pattern

Insiders
85.34%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PARNAXLAB

Google News Fri, 23 Oct 2026

Parnax Lab leads the gainers of group B on BSE - Investment Guru

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPYXVyMDRpRzd2YXdrMkpTVHJrMmhUX3VWbUdvX2ZCZGxRTW5ocE9TVnlXNXZ5bDB1b0JNX012UmhTQUY0VVN5bzhOUGFIOGdnSThxVUVIb2tla2l6cEt3Sjd4SXpWcGtWcF9Oc3dVNHFIdUtRZ2NQWXp5ZnVZRWMtN09yeFhmUnZRWS1qdU…

Google News ue, 22 Sep 2026

Parnax Lab Share Price News: Price Rise, Valuation View - Univest

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxPWkVDTzZwWkI0eWxCX0JTM3ZMR180LVpOeVdrLVNsTkVQWWNUS3pDNmV6bkJ6YjZhQW9HTFV0TzZrZ1hvemdpcVBtczhmNGdTMm9FdklJNUlYakt5aDYwd3NzekwzN1RqUTFtcFc5Q09pcjBxd0JtZXl5djYxTVEtSWlvSQ?oc=5" targe…

Google News Fri, 27 May 2022

MEDICO Stock Price and Chart — NSE:MEDICO - TradingView

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE9ibXc4MFljZWd4eHB6UjRNc0thU1lXanJqNy1vVTlYRzlkRkN5MlFCTUx1VWZGTU5zenFhNHMxY0pua0Z0aF9sUGxDQjdxZVMzZ1M3QW11eUVpVWs?oc=5" target="_blank">MEDICO Stock Price and Chart — NSE:MEDICO</a…

Google News Mon, 01 Sep 2025

SYSCHEM Stock Price and Chart — BSE:SYSCHEM - TradingView

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE42OVFnMjJ0QXQxOHpDN2RfSTVCemlkcWxyaWw3ajd5SkZkQ0Fqa1V2WUlLNlJNNkpxaXZ5eEtjRFUyUWZ1NG1ITXFvcWdBQlFnUHhBOTduVU5xTEJB?oc=5" target="_blank">SYSCHEM Stock Price and Chart — BSE:SYSCHEM…

Google News Wed, 14 Nov 2018

Parnax Lab settles case with Sebi, pays over Rs 10 lakh - India.com

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOTkV1TFVHcFdILUFEMDVYMTRrZHlmNWZkc2xfajJMNm1yTXlqX2p4eDFBMWVCS3JnaVVVczVVQnItTFVTMW9RNURVbThVYWEwcVFacVBGZHEwZXdNc2xJQS01Y1lGSldyNUtOMjZtOWNLTGxkcWNoMDEtcVhPaFYyck1aTFc1UkNIQXB5RX…

Google News ue, 15 Aug 2017

LACTOSE Stock Price and Chart — BSE:LACTOSE - TradingView

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE1jUll5dFpVUmc0YklxMXl3TkFhenVablBGRHEydGNfQWtUZWJqSjRCMm14YlJTQkpSbFpFTFIxV0U5aXNSdFEyb0hWMWUyYjB5QzJJVWVnTWFNYzJE?oc=5" target="_blank">LACTOSE Stock Price and Chart — BSE:LACTOSE…

PARNAXLAB — Frequently Asked Questions

What is the current share price of Parnax Lab Limited (PARNAXLAB)?

As of 2026-10-24 04:55 IST, Parnax Lab Limited (PARNAXLAB) trades at ₹104.05 on NSE. Its 52-week range is ₹103.94 to ₹140.78.

What is the market capitalisation of PARNAXLAB?

Parnax Lab Limited (PARNAXLAB) has a market capitalisation of ₹119.51 Cr on NSE.

What is the P/E ratio of PARNAXLAB?

PARNAXLAB trades at a trailing price-to-earnings (P/E) ratio of 13.36. The industry average P/E is 35.90. Its price-to-book (P/B) ratio is 1.42.

What is the return on equity (ROE) of PARNAXLAB?

PARNAXLAB has a return on equity (ROE) of 12.38%. Its return on capital employed (ROCE) is 14.57%.

Is PARNAXLAB a good stock to buy?

This page provides a data-driven analysis of Parnax Lab Limited (PARNAXLAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space